Cabaletta Bio, Inc.

NasdaqGS:CABA Rapport sur les actions

Capitalisation boursière : US$91.4m

Cabaletta Bio Gestion

Gestion contrôle des critères 2/4

Le PDG Cabaletta Bio est Steven Nichtberger, nommé en Jan2017, a un mandat de 7.83 ans. La rémunération annuelle totale est $ 4.81M, composée du salaire de 12.4% et des bonus 87.6%, y compris les actions et options de la société. détient directement 2.76% des actions de la société, d'une valeur de $ 2.52M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3 ans et 4.8 ans.

Informations clés

Steven Nichtberger

Directeur général

US$4.8m

Rémunération totale

Pourcentage du salaire du PDG12.4%
Durée du mandat du directeur général7.8yrs
Propriété du PDG2.8%
Durée moyenne d'occupation des postes de direction3yrs
Durée moyenne du mandat des membres du conseil d'administration4.8yrs

Mises à jour récentes de la gestion

Recent updates

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

Oct 22

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Sep 04
We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Jun 28

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

May 22
Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

Jan 31

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Dec 28
Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Sep 12
Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Jun 04
Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Feb 11
Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Oct 20
We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Jul 07
We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Mar 24
Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Dec 09
We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate

Aug 05
We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate

Cabaletta Bio EPS beats by $0.08

May 03

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Apr 12
Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

What Percentage Of Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Do Insiders Own?

Feb 19
What Percentage Of Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Do Insiders Own?

Chardan Capital initiates Cabaletta Bio with Buy rating

Jan 08

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Dec 28
We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Dosing underway in Cabaletta Bio's DSG3-CAART study in a rare skin blistering disorder

Dec 09

Cabaletta Bio +5% on Q3 results, pipeline update

Nov 10

Analyse de la rémunération des PDG

Comment la rémunération de Steven Nichtberger a-t-elle évolué par rapport aux bénéfices de Cabaletta Bio?
DateRémunération totaleSalaireBénéfices de l'entreprise
Sep 30 2024n/an/a

-US$104m

Jun 30 2024n/an/a

-US$90m

Mar 31 2024n/an/a

-US$77m

Dec 31 2023US$5mUS$597k

-US$68m

Sep 30 2023n/an/a

-US$62m

Jun 30 2023n/an/a

-US$57m

Mar 31 2023n/an/a

-US$56m

Dec 31 2022US$2mUS$569k

-US$53m

Sep 30 2022n/an/a

-US$51m

Jun 30 2022n/an/a

-US$51m

Mar 31 2022n/an/a

-US$50m

Dec 31 2021US$4mUS$542k

-US$46m

Sep 30 2021n/an/a

-US$42m

Jun 30 2021n/an/a

-US$39m

Mar 31 2021n/an/a

-US$36m

Dec 31 2020US$4mUS$516k

-US$33m

Sep 30 2020n/an/a

-US$29m

Jun 30 2020n/an/a

-US$26m

Mar 31 2020n/an/a

-US$21m

Dec 31 2019US$1mUS$437k

-US$22m

Sep 30 2019n/an/a

-US$19m

Jun 30 2019n/an/a

-US$23m

Mar 31 2019n/an/a

-US$21m

Dec 31 2018US$1mUS$213k

-US$12m

Rémunération vs marché: La rémunération totale de Steven ($USD 4.81M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 652.28K ).

Rémunération et revenus: La rémunération de Steven a augmenté alors que l'entreprise n'est pas rentable.


PDG

Steven Nichtberger (63 yo)

7.8yrs

Titularisation

US$4,808,279

Compensation

Dr. Steven A. Nichtberger, M.D., serves as managing partner of GBF Advisors, LLC. Dr. Nichtberger is an adjunct professor at The Wharton School at the University of Pennsylvania. He is Co-Founder of Cabale...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Steven Nichtberger
Co-Founder7.8yrsUS$4.81m2.76%
$ 2.5m
David Chang
Chief Medical Officer5.4yrsUS$2.10m0%
$ 0
Gwendolyn Binder
President of Science & Technologyno dataUS$2.34m0.041%
$ 37.4k
Michael Milone
Co-Founder & Co-Chair of Scientific Advisory Boardno datapas de donnéespas de données
Aimee Payne
Co-Founder & Co-Chair of Scientific Advisory Boardno datapas de donnéespas de données
Anup Marda
Chief Financial Officer5.8yrsUS$1.53mpas de données
Qing Yuan
Chief Technology Officerless than a yearpas de donnéespas de données
Samik Basu
Chief Scientific Officer3yrspas de donnéespas de données
Michael Gerard
General Counsel & Secretary3.2yrspas de donnéespas de données
Heather Harte-Hall
Chief Compliance Officer3yrspas de donnéespas de données
Nicolette Sherman
Chief Human Resources Officerno datapas de donnéespas de données
Arun Das
Chief Business Officer2.8yrspas de donnéespas de données

3.0yrs

Durée moyenne de l'emploi

51yo

Âge moyen

Gestion expérimentée: L'équipe de direction de CABA est considérée comme expérimentée (ancienneté moyenne 3 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Steven Nichtberger
Co-Founder7.8yrsUS$4.81m2.76%
$ 2.5m
Michael Milone
Co-Founder & Co-Chair of Scientific Advisory Boardno datapas de donnéespas de données
Aimee Payne
Co-Founder & Co-Chair of Scientific Advisory Boardno datapas de donnéespas de données
Richard Henriques
Independent Director5.8yrsUS$259.20k0%
$ 0
Carl June
Member of Scientific Advisory Board4.3yrspas de donnéespas de données
Mark Simon
Independent Director6.1yrsUS$260.15k0.29%
$ 267.7k
Brian Daniels
Member of Scientific Advisory Board3.4yrsUS$202.24kpas de données
Scott Brun
Independent Director3.4yrsUS$255.83k0%
$ 0
Iain McInnes
Member of Scientific Advisory Board4.8yrspas de donnéespas de données
Jay Siegel
Member of Scientific Advisory Boardno datapas de donnéespas de données
Drew Weissman
Member of Scientific Advisory Board2.9yrspas de donnéespas de données
Catherine Bollard
Independent Director5.6yrsUS$255.43k0.0021%
$ 1.9k

4.8yrs

Durée moyenne de l'emploi

63yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de CABA sont considérés comme expérimentés (ancienneté moyenne 4.8 ans).